New rheumatoid arthritis drug candidate begins first human tests

NCT ID NCT07182656

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage study is testing a new drug called CIGB-814 for safety and how the body processes it. 70 healthy volunteers aged 18-45 will receive either the drug or a placebo as a single or multiple injections. The goal is to see if it is safe enough to test in people with rheumatoid arthritis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CIGB-814

What this could lead to

If successful, this could lead to a new treatment option for rheumatoid arthritis that helps control the disease.

What could go wrong

This is a very early Phase 1 trial in healthy people, not patients. It only tests safety and dosing, not whether it works for arthritis. Many early-stage drugs fail to show benefit later.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking University People's Hospital

    RECRUITING

    Beijing, Beijing Municipality, 101149, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••